Evelo Biosciences: Julie Carretero

Evelo Biosciences, which is developing a new modality of orally delivered, systemically acting biologics, has appointed Julie Carretero as Chief People Officer to support the next phase of the company’s growth.

The Cambridge, Massachusetts biotech expects up to six clinical readouts over the next six to 12 months; and plans to build out the organization following interim Phase 2 data for its candidate EDP1815, expected in mid-2021 (EDP1815 is one of four product candidates Evelo has in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer).

With more than 20 years of experience, Carretero will assume leadership responsibilities for people initiatives - including talent acquisition and employee development - and will be a member of the Evelo Leadership Team.

She joins Evelo from FXI Corporation, a private equity held manufacturing company, and previously worked for Novartis Pharmaceuticals (most recently as Human Resources Lead for the Cardiovascular Business Unit). 

Picture: getty/oatawa​